Vinorelbine (NVB), sold under the brand name Navelbine among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer and non-small cell lung cancer. It is given by injection into a vein or by mouth.Common side effects include bone marrow suppression, pain at the site of injection, vomiting, feeling tired, numbness, and diarrhea. Other serious side effects include shortness of breath. Use during pregnancy may harm the baby. Vinorelbine is in the vinca alkaloid family of medications. It is believed to work by disrupting the normal function of microtubules and thereby stopping cell division.Vinorelbine was approved for medical use in the United States in 1994. It is on the World Health Organizations List of Essential Medicines. Medical uses
Vinorelbine is approved for the treatment of non-small-cell lung cancer. It is used off-label for other cancers such as metastatic breast cancer. It is also active in rhabdomyosarcoma. Side effects
Vinorelbine has a number of side-effects that can limit its use:
Chemotherapy-induced peripheral neuropathy (a progressive, enduring and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs), lowered resistance to infection, bruising or bleeding, anaemia, constipation, vomitings, diarrhea, nausea, tiredness and a general feeling of weakness (asthenia), inflammation of the vein into which it was injected  (phlebitis). Seldom severe hyponatremia is seen. Less common effects are hair loss and allergic reaction. Pharmacology
The antitumor activity is due to inhibition of mitosis through interaction with tubulin.
Terms oligospermia, oligozoospermia, and low sperm count refer to semen with a low concentration of sperm and is a common finding in male infertility. Often semen with a decreased sperm concentration may also show significant abnormalities in sperm morphology and motility (technically oligoasthenoteratozoospermia). There has been interest in replacing the descriptive terms used in semen analysis with more quantitative information. Diagnosis
The diagnosis of oligozoospermia is based on one low count in a semen analysis performed on two occasions. For many decades sperm concentrations of less than 20 million sperm/ml were considered low or oligospermic, recently, however, the WHO reassessed sperm criteria and established a lower reference point, less than 15 million sperm/ml, consistent with the 5th percentile for fertile men. Sperm concentrations fluctuate and oligospermia may be temporary or permanent. Sources usually classify oligospermia in 3 classes:
Mild: concentrations 10 million – 15 million sperm/mL
Moderate: concentrations 5 million – 10 million sperm/mL
Severe: concentrations less than 5 million sperm/mLThe diagnosis of oligozoospermia requires a work-up via semen analysis (listed in Male infertility). Causes
There are many causes for oligospermia including:

Pre-testicular causes
Pre-testicular factors refer to conditions that impede adequate support of the testes and include situations of poor hormonal support and poor general health including:

Hypogonadism due to various causes
Drugs, alcohol, smoking
Strenuous riding (bicycle riding, horseback riding)
Medications, including androgens. Testicular factors
Testicular factors refer to conditions where the testes produces semen of poor quality despite adequate hormonal support and include:

Age
Genetic defects on the Y chromosome
Y chromosome microdeletions
Abnormal set of chromosomes
Klinefelter syndrome
Neoplasm, e.g.